IFNB1 and myeloid sarcoma: In patients with relapsing MS, IFNβ suppresses in a portion of patients clinical and subclinical inflammatory autoimmunity via a variety of (postulated) mechanisms (reduced T cell mediated inflammation, altered function of antigen-presenting and other immune cells, stabilization of the blood-brain barrier) [3]–[10], while no signs of a general immunosuppressive effect have been noted.